LATUDA® (lurasidone HCl)
Major Depressive Disorder (adjunctive)
Key Facts
Indication
Major Depressive Disorder (adjunctive)
Phase
Launched / Phase 3
Status
Active
Company
About Sumitomo Pharma
Sumitomo Pharma's mission is to translate cutting-edge science into innovative therapies that address significant unmet medical needs, particularly in psychiatry and oncology. The company has achieved global recognition through its commercialized products like Latuda® (lurasidone) and is advancing a robust pipeline of next-generation modalities. Its strategy hinges on a balanced portfolio, combining revenue-generating assets with high-risk, high-reward R&D in gene therapy and radiopharmaceuticals, supported by strategic global partnerships and internal discovery capabilities.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (adjunctive) Drugs
| Drug | Company | Phase |
|---|---|---|
| Cariprazine (Vraylar) | Richter Gedeon | Phase III / Filed |